Table 1. Clinical Characteristics of patient donating tissue for the study.
BMI, Body Mass Index; MI, Myocardial infarction; LV, Left Ventricle; NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society; ACEI, Angiotensin Converting Enzyme Inhibitor; ARB, Angiotensin II Receptor Blocker.
| Atrial appendage patients (N = 8) | Endomyocardial biopsy patients (n = 3) | ||
|---|---|---|---|
| Age (yrs) | 58±2 | Age (yrs) | 66±3 |
| BMI (kg/m2) | 33±3 | Time from transplant to biopsy (yrs) | 1.1±0.6 |
| Sex (%male) | 75% | Sex (%male) | 67% |
| Hypertension | 75% | Hypertension | 67% |
| Dyslipidemia | 75% | Dyslipidemia | 100% |
| Ongoing Smoking | 33% | Ongoing Smoking | 0% |
| Diabetes | 25% | Diabetes | 0% |
| Thyroid disease | 25% | Thyroid disease | 0% |
| History of MI | 0% | Rejection on biopsy | 0% |
| Valvular Heart Disease | 25% | Creatinine (umol/L) | 67±6 |
| Coronary Artery Disease | 75% | Medications: | |
| Congestive Heart Failure | 0% | Anti-platelet therapy | 100% |
| LV ejection fraction | 54±7 | Beta-Blocker | 0% |
| NYHA class | 1.9±0.3 | Statins | 100% |
| CCS class | 2.3±0.7 | Diuretics | 0% |
| Creatinine (umol/L) | 94±7 | ACEI or ARB | 33% |
| Medications: | Calcium channel blocker | 33% | |
| Anti-platelet therapy | 100% | Antiarrhythmic drug | 0% |
| Beta-Blocker | 50% | Anticoagulant | 0% |
| Statins | 75% | Insulin | 33% |
| Diuretics | 25% | Oral hypoglycemic | 33% |
| ACEI or ARB | 50% | Tacrolimus | 100% |
| Calcium channel blocker | 75% | Mycophenolitic acid | 100% |
| Antiarrhythmic drug | 0% | Prednisone | 100% |
| Anticoagulant | 100% | ||
| Insulin | 0% | ||
| Oral hypoglycemics | 25% |